Abstract
Nasopharyngeal specimens for culture of Chlamydia pneumoniae were obtained from patients with community-acquired pneumonia enrolled in a randomized study comparing the novel ketolide antibiotic ABT-773 at a dose of 150 mg once a day to 150 mg twice a day, by mouth for 10 days. C. pneumoniae was eradicated from the nasopharynx of 10 of 10 (100%) microbiologically evaluable patients. MICs and MBCs for 13 isolates of C. pneumoniae from 12 patients obtained before and after therapy were performed against ABT-773. The MIC90 and MBC90 of ABT-773 were 0.015 mg/L.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Chlamydia Infections / drug therapy*
-
Chlamydia Infections / microbiology
-
Chlamydophila pneumoniae* / drug effects
-
Double-Blind Method
-
Erythromycin / analogs & derivatives*
-
Erythromycin / pharmacology
-
Erythromycin / therapeutic use*
-
Female
-
Humans
-
Ketolides*
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Nasopharynx / microbiology
-
Pneumonia, Bacterial / drug therapy*
-
Pneumonia, Bacterial / microbiology
-
Reverse Transcriptase Polymerase Chain Reaction
Substances
-
Ketolides
-
Erythromycin
-
cethromycin